Van ECK Associates Corp Has $136,000 Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Van ECK Associates Corp increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 9.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 867 shares of the company’s stock after purchasing an additional 78 shares during the quarter. Van ECK Associates Corp’s holdings in Medpace were worth $136,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Ronald Blue Trust Inc. boosted its stake in shares of Medpace by 59.8% in the 3rd quarter. Ronald Blue Trust Inc. now owns 187 shares of the company’s stock valued at $28,000 after purchasing an additional 70 shares during the last quarter. CWM LLC raised its position in shares of Medpace by 63.0% in the 3rd quarter. CWM LLC now owns 176 shares of the company’s stock valued at $28,000 after acquiring an additional 68 shares during the period. Wipfli Financial Advisors LLC acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $32,000. Point72 Hong Kong Ltd acquired a new stake in shares of Medpace in the 2nd quarter valued at approximately $42,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $46,000. Institutional investors own 82.49% of the company’s stock.

Medpace Stock Performance

Shares of MEDP stock opened at $228.84 on Friday. The company has a market capitalization of $7.12 billion, a P/E ratio of 35.10 and a beta of 1.42. The company’s 50 day moving average price is $214.84 and its two-hundred day moving average price is $183.74. Medpace Holdings, Inc. has a 52 week low of $126.94 and a 52 week high of $235.72.

Medpace (NASDAQ:MEDP – Get Rating) last posted its quarterly earnings data on Monday, October 24th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.58. Medpace had a net margin of 16.50% and a return on equity of 41.39%. The company had revenue of $383.74 million for the quarter, compared to the consensus estimate of $357.17 million. During the same period last year, the company earned $1.29 earnings per share. The firm’s revenue was up 29.8% compared to the same quarter last year. Analysts forecast that Medpace Holdings, Inc. will post 6.97 earnings per share for the current year.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 6,500 shares of Medpace stock in a transaction that occurred on Thursday, October 27th. The shares were sold at an average price of $220.53, for a total value of $1,433,445.00. Following the sale, the general counsel now directly owns 14,854 shares in the company, valued at $3,275,752.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 20.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MEDP. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, October 28th. Robert W. Baird increased their price target on shares of Medpace from $217.00 to $226.00 in a research report on Friday, January 13th. Finally, UBS Group upgraded shares of Medpace from a “sell” rating to a “neutral” rating and raised their target price for the stock from $142.00 to $238.00 in a report on Thursday, October 27th.

About Medpace

(Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.